Fact CheckerSign in

NCT05278156CompletedPhase 2

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

Source: ClinicalTrials.gov · Last updated 10 Sept 2025

Brief summary (registry, in English)

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
189 (actual)
First submitted
9 Feb 2022
Start date
19 May 2021
Primary completion date
5 Jun 2024
Lead sponsor
Celon Pharma SA
NCT number
NCT05278156

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 189
  • From 19 May 2021 to the primary completion date, 5 Jun 2024
  • 16 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • The patient has received electroconvulsive therapy.

Other illness

  • The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
  • The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
  • The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
  • The patient has chronic movement disorder that may interfere with the interpretation of study results.
  • The patient has any existing or previous history of cancer or has newly diagnosed diabetes.

Lab values

  • The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
  • The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

Other

  • The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
  • Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
  • The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
  • The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
  • The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
  • The patient is considered to be treatment resistant. .

Who the study is looking for

  • The patient has a primary diagnosis of schizophrenia confirmed by clinical interview \[SCID-5-CT\].
  • Male or female patient aged 18 to 65, inclusive, at Screening.
  • The patient's with exacerbation of psychotic symptoms
  • The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
  • The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
  • The patient of childbearing potential willing to use acceptable forms of contraception.
  • The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
  • The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
  • The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (16)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Psychiatry and Psychotheraapy of Semmelweis University
Coordinator of this site? Confirm its status
BudapestHungaryUnknown status
Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
Coordinator of this site? Confirm its status
BudapestHungaryUnknown status
Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
Coordinator of this site? Confirm its status
GyőrHungaryUnknown status
Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
Coordinator of this site? Confirm its status
KalocsaHungaryUnknown status
Psychiatry Department of Tolna County Balassa Janos Hospital
Coordinator of this site? Confirm its status
SzekszárdHungaryUnknown status
Uniwersytecki Szpital Kliniczny
Coordinator of this site? Confirm its status
BialystokPolandUnknown status
Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
Coordinator of this site? Confirm its status
BolesławiecPolandUnknown status
Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
Coordinator of this site? Confirm its status
ChoroszczPolandUnknown status
Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
Coordinator of this site? Confirm its status
Gmina ŚwieciePolandUnknown status
Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
Coordinator of this site? Confirm its status
Ivano-FrankivskUkraineUnknown status
Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
Coordinator of this site? Confirm its status
KyivUkraineUnknown status
Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
Coordinator of this site? Confirm its status
KyivUkraineUnknown status
Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
Coordinator of this site? Confirm its status
LvivUkraineUnknown status
Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
Coordinator of this site? Confirm its status
LvivUkraineUnknown status
Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
Coordinator of this site? Confirm its status
TernopilUkraineUnknown status
Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education
Coordinator of this site? Confirm its status
VinnytsiaUkraineUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.